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ABSTRACT
Targeting particular mRNAs for degradation is a
fascinating approach to achieve gene silencing.
Here we describe a new gene silencing tool exploit-
ing a cell-penetrating, nucleic-acid hydrolyzing,
single-domain antibody of the light-chain variable
domain, 3D8 VL. We generated a synthetic library
of 3D8 VL on the yeast surface by randomizing
residues located in one of two b-sheets. Using
18-bp single-stranded nucleic acids as target
substrates, including the human Her2/neu-targeting
sequence, we selected 3D8 VL variants that had
 100–1000-fold higher affinity and  2–5-fold
greater selective hydrolyzing activity for target
substrates than for off targets. 3D8 VL variants effi-
ciently penetrated into living cells to be accumula-
ted in the cytosol and selectively decreased the
amount of target sequence-carrying mRNAs as
well as the proteins encoded by these mRNAs with
minimal effects on off-target genes. In particular,
one 3D8 VL variant targeting the Her2 sequence
showed more efficient downregulation of Her2
expression than a small-interfering RNA targeting
the same Her2 sequence, resulting in apoptotic
cell death of Her2-overexpressing breast cancer
cells. Our results demonstrate that cell-penetrating
3D8 VL variants with sequence-selective, nucleic-
acid-hydrolyzing activity can selectively degrade
target mRNAs in the cytosol, providing a new gene
silencing tool mediated by antibody.
INTRODUCTION
Gene silencing by targeting speciﬁc genes for degradation,
particularly at the mRNA level, is an invaluable tool for
gene function analysis and a powerful therapeutic strategy
for human diseases, including cancer and viral infections
(1,2). Nucleic-acid based approaches that speciﬁcally rec-
ognize and hydrolyze particular regions of targeted RNA
have been developed for this purpose, including antisense
oligonucleotides and interference RNAs (RNAi) (1,2).
The RNAi technique is now readily available, in which
21–23bp double-stranded (ds)-RNAs, so-called small
interfering RNAs (siRNA), cause sequence-speciﬁc degra-
dation of complementary mRNAs (3,4). Although
siRNAs can be directly designed for the target sequence
based on Watson–Crick base pairing, their practical appli-
cation has been limited by several factors, including
cellular delivery, nuclease susceptibility and oﬀ-target
eﬀects (1–4).
Another approach for degrading cytosolic RNAs is the
use of protein-based RNases (5) and DNA/RNA-
hydrolyzing monoclonal antibodies (mAbs) (6,7), which
can penetrate into living cells and degrade cytosolic
RNAs. However, these approaches lack high sequence-
speciﬁcity, leading to signiﬁcant cytotoxicity (5–7).
Although some RNases have been fused with peptides
that confer both cell-penetrating and sequence-speciﬁc
recognition abilities (8,9), these fused RNases cannot be
used as a general gene-silencing tool for other genes.
As an alternative approach to conventional techniques,
we here describe proof-of-concept for an ‘interfering
transbody’ technology, in which a cell-penetrating
antibody (transbody) (10,11) equipped with sequence-
speciﬁc, nucleic-acid-hydrolyzing activity selectively rec-
ognizes and hydrolyzes the target mRNA in the cytosol
of living cells, leading to gene silencing (Figure 1A).
Recently we reported a sequence-non-speciﬁc DNA/
RNA-hydrolyzing single-domain antibody of the light-
chain variable domain, 3D8 VL (7,12,13), which has
cell-penetrating ability. Here, from a yeast surface-
displayed 3D8 VL library generated by randomizing
potential base-interacting residues, we isolated 3D8 VL
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hydrolyzing activity against 18-bp single-stranded (ss)-
nucleic acids. The sequence-selective 3D8 VL variants
penetrated into living cells and selectively decreased the
amounts of the target mRNAs as well as the proteins
expressed by these mRNAs, with minimal eﬀects on oﬀ-
target genes. In particular, a Her2/neu-targeting 3D8 VL
variant induced apoptotic cell death of Her2-
overexpressing cells by down-regulating Her2 expression
after cellular internalization. Our results provide a new
gene silencing tool mediated by interfering transbody,
which would have potential applications in anti-cancer
or anti-viral therapies.
MATERIALS AND METHODS
Materials
All oligonucleotides were synthesized from Integrated
DNA technologies (Coralville, IA), unless otherwise
speciﬁed. Target substrates of 18-bp ss-DNAs and ss-
RNAs, G18 (50-GGG GGG GGG GGG GGG GGG-30
for ss-DNA; (G4U)3G3 for ss-RNA) and Her218 (50-AAT
TCC AGT GGC CAT CAA-30 for ss-DNA; 50-AAU
UCC AGU GGC CAU CAA-30 for ss-RNA), were
synthesized with or without 50-biotinylation (12,13). Oﬀ-
target 18bp ss-DNAs with contiguous stretches of single
nucleobases, such as T18,C 18 and A18, or random
sequences N18 (N=A/T/G/C) were also synthesized
with or without 50-biotinylation. An oﬀ-target substrate
of 18-bp ss-RNA N18 (N=A/U/G/C) was synthesized
as above. To construct enhanced green ﬂuorescent
protein (EGFP) (the GFP carries two mutations of
Phe64Leu and Ser65Thr) reporter plasmid, the target
sequence of G18 and Her218 was placed between the
ATG start codon and EGFP coding sequence in the
pEGFP-N1 plasmid (Clontech), resulting in pG18-EGFP
and pHer218-EGFP, respectively. The full-length Her2
cDNA (NCBI accession no. M11730) was subcloned
into pcDNA3.1(+) with NheI and BamHI sites, resulting
in pcDNA3-Her2. Her218-siRNA, which has the sequence
50- AAU UCC AGU GGC CAU CAA AdTdT-30, was
synthesized at Bioneer Co. (Daejeon, Korea). All other
reagents were analytical grade, the details of which are
provided in the Supplementary Data.
3D8 VL library construction and screening
The gene encoding 3D8 VL derivative 4M, which has four
mutations of Q42R, Y49H, W50R and H94A, compared
with 3D8 VL wild-type (WT) (NCBI accession no.
AAF79129) (12,13), was subcloned in-frame into the
yeast surface display plasmid, pCTCON (14). Using 3D8
VL 4M as a template (Supplementary Figure S1), the 3D8
VL library was generated by serial overlapping PCRs
to reconstitute full-size products using ﬁve partially
overlapping oligonucleotides and two ﬂanking oligo-
nucleotides, which were designed to randomize targeted
mutation residues at the in C-, C0-, F-strands with the
NNB codon. Library construction (Supplementary
Figure S1) and library screening against biotinylated-
target ss-DNAs (Supplementary Figure S2) were
conducted using previously described protocols (14)
(also see Supplementary Data for details).
Protein preparation and biochemical analyses
3D8 VL WT and HW1 scFv were prepared from the
supernatant of bacterial culture, as essentially described
previously (12,13,15). After genes encoding 3D8 VL
variants, including 4M, were subcloned from the yeast
surface display vector into in frame the bacterial cytosolic
expression plasmid of pETdwHis using NheI/BamHI sites
(15), they were expressed in Escherichia coli BL21 (DE3).
While 4M expressed solubly in the cytosol of E. coli was
puriﬁed using its C-terminus 6 His tag (12,13), isolated
3D8 VL variants expressed dominantly in insoluble form
of inclusion body were refolded and puriﬁed as described
previously (16). The yield of puriﬁed protein was  2–3mg
out of 1-l ﬂask culture. Protein concentrations were deter-
mined using the Bio-Rad protein assay kit. Biochemical
analyses of 3D8 VLs, such as DNA- and RNA-
hydrolyzing assays on agarose gels (7,13,17) and surface
plasmon resonance (SPR) analysis (12,13) were described
previously, the details of which are provided in the ﬁgure
legends and Supplementary Data.
Sequence-speciﬁc nucleic-acid-hydrolyzing assays
Sequence-speciﬁc ss-DNA and ss-RNA-hydrolyzing
kinetic assays of 3D8 VL WT and its variants were
carried out by ﬂuorescence resonance energy transfer
(FRET)-based cleavage assay using 18-bp target and
oﬀ-target substrates, which were double-labeled with a
6-carboxyﬂuoroscein (FAM
TM) at the 50-terminus and
a black-hole quencher (BHQ-1) at the 30-terminus
(Integrated DNA Technologies) (7,18). For ss-DNA
FRET substrates, the following substrates were used:
A18,5 0-FAM-AAA AAA AAA AAA AAA AAA-BHQ-
1-30;T 18,5 0-FAM-TTT TTT TTT TTT TTT TTT-BHQ-1-
30;C 18,5 0-FAM-CCC CCC CCC CCC CCC CCC-BHQ-
1-30;( G 4T)3G3,5 0-FAM-GGG GTG GGG TGG GGT
GGG-BHQ-1-30; Her218,5 0-FAM-AAT TCC AGT
GGC CAT CAA-BHQ-1-30;N 18,5 0-FAM-NNN NNN
NNN NNN NNN NNN-BHQ-1-30 (N=A/T/G/C). For
ss-RNA FRET substrates, the following two substrates
were used: Her218,5 0-FAM-AAU UCC AGU GGC
CAU CAA-BHQ-1-30;N 18,5 0-FAM-NNN NNN NNN
NNN NNN NNN-BHQ-1-30 (N=A/U/G/C). FRET
reactions were initiated at 37 C in 96-well Greiner black
plate (Sigma-Aldrich) by adding 100ml of 3D8 VLs (ﬁnal
100nM) to 100ml of samples containing various concen-
trations of dual-labeled substrates (16nM–2mM) in TBS
buﬀer with 2mM MgCl2 for ss-DNAs or without 2mM
MgCl2 for ss-RNAs. Increase of ﬂuorescence intensity due
to the DNA/RNA hydrolysis was immediately measured
by excitation at 480 and emission at 525nm for 30min
at 30s interval in a ﬂuorescence microplate reader
(Molecular Devices). Fluorescence did not signiﬁcantly
increase over time when 10mM of the dual-labeled
oligonucleotides were incubated in reactions without
3D8 VLs. The raw ﬂuorescence data were corrected for
background signal determined in the absence of proteins
and then scaled so that all the initial values were the same
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value was converted into substrate concentration using
the standard curve, in which ﬂuorescence intensity
changes were plotted as a function of substrate concentra-
tions that were completely digested by DNase I for
ss-DNA substrates and bovine pancreatic RNase A
(Invitrogen) for ss-RNA substrates (18). Then initial rate
constants (V) at each substrate concentration were deter-
mined by linear regression over the initial linear regions
(between 0 and 500s) of the normalized data using
Softmax pro software (Molecular Devices). The
apparent enzymatic kinetic parameters, Km and Vmax,
were determined by ﬁtting the initial rate constants (V)
versus substrate concentrations (S) into the Michaelis–
Menten equation [V=(Vmax[S])/(Km+[S])] and
Lineweaver–Burk equation using Sigmaplot 2002
software (SPSS Inc.) (12,18). All experiments were per-
formed in triplicate and the results are expressed as
mean±standard deviation (SD). Signiﬁcant diﬀerence
was determined using two-tailed Student’s t-test versus
the control N18 substrate on Excel software (Microsoft
Inc.). A P-value of<0.01 was taken as statistically
signiﬁcant.
Cell penetration
Human cervical carcinoma HeLa, breast carcinoma SK-
BR-3 and MDA-MB-231 cells were from American Type
Culture Collection (ATCC, Manassas, VA) and cultured
in DMEM (Dulbecco’s Modiﬁed Eagle Medium) supple-
mented with 10% (v/v) fetal bovine serum, 100units/ml
penicillin, and 100mg/ml streptomycin (Invitrogen) in a
humidiﬁed 5% CO2/95% air atmosphere at 37 C
(7,15,19). All of the cell lines were routinely screened for
Mycoplasma contamination. Cell penetration experiments
and subsequent various analyses were performed as
described previously (7,12,15). Cells were seeded at a
density of  5 10
5cells/well in 6-well plate (for ﬂow
cytometry, RT–PCR, western blotting, and cell viability
assays) or  5 10
4cells/well in 24-well plate over glass
coverslips (for confocal microscopy) the day before use,
and pre-incubated in serum-free DMEM for 30min at
37 C prior to the treatment of proteins and/or reagents.
Then the cells were incubated with 3D8 VLs (each 10mM)
for 2h at 37 C with or without pre-treatment with 100IU/
ml soluble heparin, chloropromazine (10mg/ml), methyl-
b-cyclodextrin (5mM) and cytochalasin D (1mg/ml) for
30min at 37 C, washed and then further incubated
for the indicated periods prior to subjecting to vari-
ous analyses, as speciﬁed in ﬁgure legends. Cell viability
was analyzed using a colorimetric MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-
based cell growth determination kit (Sigma) (7,15,19).
The percentage of apoptotic cells was quantiﬁed by ﬂow
cytometry after ﬂuorescent staining with Annexin-V-FITC
and propidium iodide (PI) (19).
Cell transfection
All transfections were performed using Lipofectamine
2000 (Invitrogen Inc.) with plasmid DNA (each 0.5mg)
or Her218-siRNA (500nM) following the manufacturer’s
instructions (7). For HeLa cells transfected with plasmid
of pEGFP-N1, pG18-EGFP, or pcDNA3-Her2, the cells
were treated for 2h at 37 C with 3D8 VLs (10mM) after 12
or 24h post-transfection, washed and then further
incubated for the indicated periods prior to subjecting to
various analyses. In experiment with SK-BR-3 cells, the
cells grown  50% conﬂuency ( 5 10
5cells in 6-well
plates) were transfected with Her218-siRNA as above,
prior to subjecting to various analyses.
Confocal ﬂuorescence microscopy
Confocal ﬂuorescence microscopic analyses of the cells
were performed as described previously (7,15). Brieﬂy,
the cells were washed twice with cold PBS, ﬁxed with
2% paraformaldehyde in PBS for 10min at 25 C, and
then permeabilized with Perm-buﬀer (1% BSA, 0.1%
saponine, 0.1% sodium azide in PBS) for 10min at
25 C. For staining of internalized 3D8 VLs, the cells
were blocked with 2% BSA in PBS for 1h, incubated
with rabbit anti-3D8 polyclonal antibodies (7), followed
by TRITC-anti-rabbit IgG. Nucleus was stained with
DAPI (40,6-diamidino-2-phenylindole dihydrochloride)
(Vector Labs) during the last 10min of incubation at
25 C. Cells on coverslip were mounted in Vectashield
anti-fade mounting medium (Vector Labs), and observed
with Zeiss LSM 510 laser confocal microscope and
analyzed with Carl Zeiss LSM Immage software.
Flow cytometry
For the quantiﬁcation of EGFP expression in HeLa cells
treated as above, the suspended cells with trypsin were
washed twice with 1ml ice-cold PBS and then directly
subjected to ﬂow cytometry on a Becton Dickinson
FACSCalibur
TM (7,15). For the cells transfected with
EGFP and/or treated with 3D8 VLs (10mM) for cellular
internalization as described above, the suspended cells
with trypsin were treated once more with 0.1% trypsin
for 3min at 37 C to wash oﬀ the surface bound proteins
(7). After washings with ice-cold PBS once, the cells were
ﬁxed and permeabilized as the procedures described in
above ‘confocal ﬂuorescence microscopy’. The cells were
washed with ice-cold PBS twice, labeled with rabbit anti-
3D8 polyclonal antibodies followed by TRITC-anti-
rabbit, and then analyzed using the ﬂow cytometry. In
experiment with the SK-BR-3 cells transfected with
Her218-siRNA or exposed to 3D8 VLs as above, cell-
surface expression levels of Her2 were monitored by
immunoﬂuorescent labeling of rabbit anti-Her2 mAb
(1h on ice) and then goat FITC-labeled anti-rabbit IgG
(1h on ice) (7,15). For each test,  1 10
4cells were
analyzed.
Reverse transcription (RT) PCR
To monitor mRNA levels in cells, semi-quantitative RT–
PCR was performed following the standard procedures
(7,20). Total cellular RNA was extracted from speciﬁed
cells, using the Trizol (Gibco Invitrogen), according to
the manufacture’s instruction. Aliquots ( 1mg) of total
RNA were used for ﬁrst strand complimentary DNA
(cDNA) synthesis using PreMix cDNA synthesis kit
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cDNA was then diluted and used as a template to amplify
transcripts speciﬁc for 3D8 VLs, EGFP, Her2, and/or
b-actin by PCR with the same number of cycles
(30 cycles) (7). The endogenous gene, b-actin, was served
to normalize the total amount of mRNA used in each
sample (20). The PCR products were then applied to 1%
agarose gel electrophoresis followed by ethidium bromide
staining.
Western blotting
Western blotting for cell lysates treated as speciﬁed
in ﬁgure legends was performed following the standard
procedure, using primary antibodies speciﬁc for target
molecules (7,15,19). The appropriate secondary IgG con-
jugated to horse radish peroxidase (Zymed Laboratories)
was used for developing by chemiluminescence
(Amersham Pharmacia Biotech).
RESULTS
3D8 VL library design and construction
3D8 VL WT possess intrinsic DNA/RNA-hydrolyzing
activity without sequence speciﬁcity in the presence of a
divalent metal ion, including Mg
2+ and Co
2+ (12,13,17).
Although the structure of the complex between 3D8 VL
WT and DNA/RNA is currently unavailable, the recently
resolved 3D8 VL WT structure complexed with a phos-
phate mimetics and Co
2+ (17) suggests that the residues of
Leu33, Tyr49, Trp50, Lys89 and Ser91 are the putative
DNA/RNA-hydrolyzing catalytic site. These residues
are located in the upper part on one of two b-sheets
(Figure 1B), indicating that 3D8 VL might interact with
DNA/RNA using the groove formed by the three-
stranded b-sheet (C-, C0- and F-strands). The eﬃcient
DNA/RNA-hydrolyzing activity of the 3D8 VL WT
derivative 4M (Figure 2A and B), which has four substi-
tutions of Q42R, Y49H, W50R and H94A in the groove
(Supplementary Figure S3) (13,17), supported the
rationale of randomizing residues on the C0-, C- and F-
strands to isolate DNA/RNA sequence-speciﬁc 3D8 VL
variants.
We constructed a yeast surface-displayed 3D8 VL
library on the template of 4M by performing successive
overlapping PCR mutagenesis, using partially overlapping
oligonucleotides designed to introduce random mutations
with a degenerate codon NNB at the 15 targeted residues
of the C- (35–39 residues), C0- (44–48 residues) and F-
strands (84–88 residues) (Figure 1C and Supplementary
Figure S1). The NNB codon encodes all 20 amino
acids with a reduced stop codon frequency (2.1%) (21).
The constructed 3D8 VL library showed the diversity of
 8 10
7, which sparsely sampled the theoretical sequence
space (>3 10
19). The initial library with random
mutations with 20 possible amino acids at the targeted
regions was expressed well on the yeast cell surface
(Supplementary Figure S1).
Isolation of 3D8 VL variants against target 18-bp
ss-DNA substrates
For model target substrates, we used two 18-bp ss-DNA
substrates, contiguous guanine nucleobase (G18) and the
Her2/neu-targeting sequence (Her218). The Her218
sequence, corresponding to positions 2391–2408 of the
Her2/neu gene, was designed according to an algorithm
to search siRNA target sequences (22). The oncogene
Her2 is widely overexpressed in many human epithelial
tumors, making it an attractive target for anti-cancer
agents (22,23). The ss-DNA was employed as a substrate
rather than ss-RNA because ss-RNA is highly sensitive to
self-hydrolysis. Using two rounds of magnetic activated
cell sorting (MACS) followed by four rounds of ﬂuores-
cence activated cell sorting (FACS) with a high salt
(300mM NaCl) containing buﬀer and oﬀ-target substrates
as competitors to counterselect against non-speciﬁc
binders, six clones against G18 and ﬁve against Her218
were isolated and designated 4MG1-6 and 4MH1-5,
respectively (Supplementary Figures S2 and S3). The
isolated 3D8 VL variants contained 5–15 substitutions
out of the 15 targeted residues (Supplementary Figure S3).
Biochemical characterization of isolated 3D8 VL variants
All of the isolated variants were subcloned in-frame into a
bacterial cytoplasmic expression plasmid. While 3D8 VL
WT and 4M were expressed solubly in E. coli (12,13),
all of the isolated 3D8 VL variants were expressed
dominantly in insoluble form of inclusion body. Thus
they were refolded and puriﬁed with>90% purity, as
shown in SDS–PAGE analyses (Supplementary Figure
Figure 1. (A) Schematic diagrams showing the concept of the
interfering transbody. Cell-penetrating antibody (transbody) equipped
with sequence-speciﬁc nucleic-acid-hydrolyzing activity penetrates into
the cytosol of living cells and preferentially recognizes and hydrolyzes
the target mRNA, leading to target gene silencing. (B) Structural char-
acteristics of 3D8 VL. Three-dimensional structure of the complex
between 3D8 VL WT and Co
2+ (gray ball) (PDB code 3BD5) (17).
The putative catalytic residues are highlighted and described in detail in
the text. Each b-strand is indicated by a diﬀerent color code. (C) 3D8
VL library generation scheme. The library was generated by
randomizing 15 putative nucleic-acid binding residues in the groove
composed of the C- (35–39 residues), C0- (44–48 residues) and
F-strands (84–88 residues) with a degenerate codon of NNB (N=A/
T/G/C, B=C/G/T) based on 3D8 VL 4M as a template
(Supplementary Figure S1). Numbering is according to the Kabat def-
inition (12). Amino acids and nucleotide bases are indicated in
single-letter code according to IUPAC.
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variants maintained DNA-hydrolyzing catalytic activity
by agarose gel electrophoresis using the supercoiled
plasmid of pUC19 as a substrate. Most of the variants
eﬃciently hydrolyzed the substrate in the presence of
Mg
2+, but not EDTA, demonstrating that they retain
DNA-hydrolyzing activity in a Mg
2+-dependent manner
(Figure 2A), similar to the parents of 3D8 VL WT and 4M
(12,13). Among them, we focused further investigation on
4MG3 and 4MG5 isolated against G18 as well as 4MH2
isolated against Her218, which showed the most eﬃcient
DNA-hydrolyzing activities.
The chosen 3D8 VL variants, including 3D8 VL WT
and 4M, also eﬃciently hydrolyzed total cellular
RNAs extracted from HeLa cells even in the presence of
EDTA (Figure 2B), demonstrating that 3D8 VLs possess
RNase activity without requirement of divalent metal
ions, like RNase A (24). However, an irrelevant HW1
scFv (15) puriﬁed from bacterial cells using the same
procedure with that of 3D8 VLs did not show the RNA-
hydrolyzing activity. This demonstrated that the RNA-
hydrolyzing activity of 3D8 VLs was their intrinsic
property, but not due to co-puriﬁed bacterial nucleases.
Taken altogether, the 3D8 VLs have both DNase and
RNase activity in vitro, like 3D8 scFv (7,12,13).
Size exclusion chromatography (SEC) analyses
demonstrated that 3D8 VLs (20mM  260mg/ml) were
eluted as single peaks that correspond to an apparent
Figure 2. Biochemical characterization of representative 3D8 VL variants selected against ss-DNA G18 (4MG3 and 4MG5) and Her218 ss-DNA
(4MH2), compared with 3D8 VL WT and 4M. (A) DNA hydrolyzing activity analyses of primarily isolated 3D8 VLs selected against ss-DNA G18
(4MG1-4MG6) and Her218 ss-DNA (4MH1-4MH5) by agarose gel electrophoresis, compared with 3D8 VL WT and 4M. The supercoiled plasmid of
pUC19 (2.2nM) was incubated with 3D8 VLs (5mM) for 1h at 37 C in the TBS buﬀer, pH 7.4, containing 2mM MgCl2 (indicated as ‘Mg’) or
50mM EDTA (indicated as ‘E’). The reaction mixtures were analyzed by electrophoresis on 0.7% agarose gels, and then stained with ethidium
bromide. The arrows indicate supercoiled (sc), linear (lin) and relaxed circular (rc) DNAs. The samples incubated with only buﬀer alone and
molecular mass markers were designated as ‘B’ and ‘M’, respectively. (B) RNA-hydrolyzing activity of 3D8 VLs, including WT, 4M, G18-selective
4MG3 and 4MG5, and Her218-selective 4MH2. Total cellular RNA (1mg) extracted from HeLa cells were incubated at 37 C for 2hin TBS buﬀer,
pH 7.4, containing 2mM MgCl2 (indicated as ‘Mg’) or 50mM EDTA (indicated as ‘E’) with 3D8 VLs (0.1mM), RNase A (1U), irrelevant HW1
scFv protein (0.1mM) as a negative control prior to gel electrophoresis. The bands corresponding to rRNAs of 28S and 18S are indicated. (C) SEC
elution proﬁles of representative 3D8 VLs ( 12kDa). Each protein (20mM  260mg/mlin TBS, pH7.4) indicated in diﬀerent lines was injected and
chromatograms were obtained by absorbance at 280nm. Arrows indicate the elution positions of mass standard markers (Sigma) [BSA (66kDa),
ovalbumin (45kDa), chymotrypsinogen A (25kDa), ribonuclease A (13.7kDa)]. (D) Far-UV CD spectra of representative 3D8 VLs (100mg/ml
in TBS, pH7.4) to monitor the secondary structure are shown.
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are existing in monomeric form in solution at concentra-
tions higher than used in DNA- and RNA-hydrolyzing
assays (Figure 2C). This result indicates that 3D8
VLs hydrolyze both DNA and RNA in monomeric
form. Secondary structures of the 3D8 VL variants,
4MG3, 4MG5 and 4MH2, determined by far-UV
circular dichroism (CD) spectroscopy exhibited very
similar spectra to those of 3D8 VL WT and 4M, exhibiting
a negative maximum of mean residue ellipticity  217nm
(Figure 2D), which is typical for the immunoglobulin
fold (12). This data suggested that the extensive muta-
tions incorporated into the inner b-strands of the 3D8
VL variants did not signiﬁcantly aﬀect the unique second-
ary structure.
Selected 3D8 VL variants preferentially bind to
hydrolyze target substrates
The speciﬁcity and aﬃnity of the selected 3D8 VLs for their
respective target ss-DNA/RNA (G18 and Her218) and oﬀ-
targets (A18,T 18,C 18 and N18) were evaluated using SPR
technique (13). The kinetic binding parameters are
summarized in Table 1. 3D8 VL WT and 4M exhibited
indistinguishable binding aﬃnities (KD  10
 5M) for all
tested ss-DNA/RNA substrates (12,13), except for the
preferential bindings (KD  10
 6M) of 4M and 4MG5
for ss-DNA T18 and C18 substrates. In contrast, the 3D8
VL variants displayed  100–1000-fold tighter binding (KD
 10
 8M of 4MG3 and 4MG5 against ss-DNA/RNA G18;
KD  10
 7M of 4MH2 against ss-DNA/RNA Her218)t o
target substrates than to oﬀ-targets (KD  10
 5M), which
was mainly due to the decreased dissociation rate constants
(koﬀ)of thetargetsubstrates(Table 1). Thisresultindicated
that, even though 18-bp ss-DNAs were used as screening
probes, the selected 3D8 VL variants maintained preferen-
tial binding speciﬁcity for the target substrates with the
same sequences in ss-RNA form.
We next determined the target sequence-speciﬁc
hydrolyzing activity of 3D8 VL variants by using a
FRET-based cleavage assay with 18-bp target and oﬀ-
target ss-DNAs as substrates, which were double-labeled
with a ﬂuorophore (FAM) at 50-terminus and its quencher
(BHQ-1) at 30-terminus (Figure 3) (7,18). The substrate-
hydrolyzing can be monitored by following the ﬂuores-
cence intensity increase caused by the 6-FAM release
from its quencher BHQ-1 due to the hydrolysis (7,18).
The reaction velocity of 3D8 VLs exhibited saturation
Table 1. Kinetic binding parameters for the interactions of 3D8 VLs with target and oﬀ-target 18-bp ss-DNAs or ss-RNAs, which were
monitored by SPR
a
3D8
VLs
Kinetic
parameters
ss-DNA substrates (ss-RNA substrates)
b
A18 T18 C18 G18[ss-RNA
(G4U)3G3]
c
Her218(ss-RNA) N18(ss-RNA)
WT kon (M
 1s
 1)(  10
3) 0.13±0.04 0.67±0.02 0.78±0.04 0.71±0.01
(0.39±0.02)
1.63±0.30
(0.31±0.02)
0.41±0.03
(0.56±0.02)
koﬀ (s
 1)(  10
 3) 3.24±0.21 6.82±0.13 9.73±0.88 8.26±0.62
(6.27±0.15)
35.2±2.3
(5.39±0.24)
15.4±2.7
(19.3±1.3)
KD (M) ( 10
 7) 239±13 102±15 126±13 116±15
(159±12)
215±5.3
(174±15)
375±4.2
(344±16)
4M kon (M
 1s
 1)(  10
3) 0.60±0.02 3.95±0.21 5.81±0.25 0.49±0.13
(0.54±0.09)
0.24±0.02
(0.14±0.01)
0.96±0.02
(0.49±0.13)
koff( s
 1)(  10
 3) 7.32±0.70 5.80±0.09 5.88±0.71 5.18±0.10
(5.63±0.45)
5.49±0.47
(3.45±0.98)
10.3±1.8
(6.04±0.28)
KD (M) ( 10
 7) 122±12 14.7±1.6 10.1±1.6 105±23
(104±19)
233±2.7
(252±19)
107±3.5
(123±27)
4MG3 kon (M
 1s
 1)(  10
3) 0.14±0.03 0.25±0.02 3.07±0.32 1.17±0.3
(1.11±0.08)
0.24±0.04
(0.15±0.02)
0.38±0.02
(0.25±0.03)
koﬀ (s
 1)(  10
 3) 5.24±0.95 2.80±0.19 3.53±0.41 0.09±0.01
(0.08±0.01)
7.55±0.89
(6.80±0.55)
9.37±0.97
(4.26±0.36)
KD (M) ( 10
 7) 371±28 112±22 115±14 0.76±0.04
(0.72±0.05)
313±24
(441±23)
249±31
(171±12)
4MG5 kon (M
 1s
 1)(  10
3) 0.26±0.02 0.89±0.04 0.51±0.03 9.02±0.77
(8.18±0.08)
0.45±0.05
(0.56±0.07)
0.13±0.03
(0.16±0.03)
koﬀ (s
 1)(  10
 3) 7.92±0.24 3.13±0.12 1.92±0.11 0.84±0.05
(0.72±0.04)
5.32±0.82
(7.20±0.31)
7.25±0.87
(9.43±0.22)
KD (M) ( 10
 7) 303±19 35.0±3.6 37.7±2.9 0.93±0.03
(0.88±0.07)
118±29
(129±28)
557±54
(590±22)
4MH2 kon (M
 1s
 1)(  10
3) 0.13±0.01 0.25±0.05 0.43±0.03 0.42±0.07
(0.23±0.01)
4.41±0.13
(2.45±0.10)
0.17±0.01
(0.18±0.02)
koﬀ (s
 1)(  10
 3) 2.54±0.21 2.51±0.61 4.31±0.87 4.53±0.82
(3.22±0.17)
0.94±0.07
(0.38±0.02)
7.20±0.66
(5.44±0.90)
KD (M) ( 10
 7) 194±21 103±17 100±22 107±3.4
(143±11)
2.13±0.13
(1.47±0.27)
427±29
(308±21)
aEach value represents the mean±SD of two independent experiments. In each experiment, at least ﬁve data sets were used in the determination of
the kinetic constants.
bThe values for ss-RNA substrates, G18, Her218 and N18, were presented in the parenthesis.
cDue to the diﬃculty in synthesizing 50-biotinylated ss-RNA G18, ss-RNA (G4U)3G3 was used as the G18 substrate.
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tration, demonstrating that 3D8 VLs act as nucleic-
acid-hydrolyzing enzymes with substrate preferences.
Lineweaver–Burk plot analyses showed that 3D8 VL
WT and 4M exhibited similar hydrolyzing eﬃciencies
(kcat/Km  2.1–3.4 10
 6nM
 1s
 1) with only slight dif-
ferences in Km and kcat for all of the ss-DNA substrates
tested (Table 2), conﬁrming their sequence non-speciﬁc
hydrolyzing activity (12,13). In contrast, 3D8 VL
variants hydrolyzed their respective target substrates
 2–5-fold more eﬃciently (kcat/Km  7.1–7.8 
10
 6nM
 1s
 1) than the oﬀ-targets (kcat/Km  1.6–
4.1 10
 6nM
 1s
 1) due to their improved substrate
aﬃnity (Km) and catalytic rates (kcat) (Table 2),
demonstrating that they preferentially recognized and
degraded target substrates. Thus, we designated 4MG3
and 4MG5 as G18-selective and 4MH2 as Her218-selective
3D8 VL variants. When the sequence-selective
hydrolyzing activity of 4MH2 was further evaluated for
the substrates with the same sequence in ss-RNA
form, 4MH2 exhibited  2-fold higher hydrolyzing eﬃ-
ciency for the target ss-RNA Her218 (kcat/Km
 10.0 10
 6nM
 1s
 1) than the oﬀ-target ss-RNA N18
(kcat/Km  5.1 10
 6nM
 1s
 1) (Table 2 and Figure 3B),
like the cases for the ss-DNA Her218. However, the other
3D8 VLs showed indistinguishable catalytic eﬃciency
for both ss-RNA Her218 and N18, indicative of their
sequence-nonspeciﬁc hydrolyzing activities for even
ss-RNAs. The catalytic eﬃciencies (kcat/Km) of 3D8 VLs
for the ss-RNAs (Her218 and N18) were slightly higher
than those for the corresponding ss-DNAs by the
marginal improved substrate aﬃnity (Km) and turnover
number (kcat) for the ss-RNAs, most likely due to the
diﬀerence in metal ion-independent and -dependent
catalytic mechanism for ss-RNAs and ss-DNAs, respec-
tively (Figure 2). The Km values of the 3D8 VL variants
Figure 3. Sequence-speciﬁc ss-DNA/RNA hydrolyzing assay of 3D8 VL variants selected against ss-DNA G18 (4MG3 and 4MG5) and Her218
(4MH2), compared with 3D8 VL WT and 4M. (A and B) Substrate-concentration dependent initial hydrolyzing velocity (V) of 3D8 VLs were plotted
against various 18-bp ss-DNA substrate (S) concentrations (A) or 18-bp ss-RNA substrate (S) concentrations (B). Each protein (100nM) was
incubated at 37 C with the indicated substrates (16nM to 2mM), which were double-labeled with 6-FAM at 50-terminus and its quencher BHQ-1 at
30-terminus and real-time ss-DNA/RNA hydrolyzing kinetic data were monitored by the ﬂuorescence intensity increase caused by the 6-FAM release
from its quencher BHQ-1 due to the hydrolysis (7,18). Due to the diﬃculty in synthesizing double-labeled ss-DNA G18. 18-bp ss-DNA substrate of
(G4T)3G3 was used as the G18 substrate. The detailed enzymatic kinetic parameters are shown in Table 2. All data points are represented as
mean±SD of three experiments. Lines through mean values represent a mathematical ﬁt of the data using the Michaelis–Menten equation.
1602 Nucleic Acids Research, 2010,Vol.38, No. 5for each substrate were not strictly correlated with
the substrate aﬃnity (KD) obtained by SPR (Table 1),
indicating a complicated catalytic mechanism in
solution. Compared with endonuclease of RNA-induced
silencing complex (RISC) involved in RNAi (25), the Km
and kcat values of 3D8 VL variants were  10-fold higher
and slightly lower, respectively, resulting in overally  10-
fold lower catalytic eﬃciency for target substrates.
3D8 VLs eﬃciently internalize into living cells and
accumulate in the cytosol
The recently identiﬁed ability of 3D8 scFv to penetrate
into living cells and accumulate in the cytosol without
translocating to the nucleus (7) led us to investigate
whether 3D8 VLs act similarly. Indeed, human cervical
carcinoma HeLa and breast carcinoma SK-BR-3 living
cells treated with 3D8 VLs (WT, 4MG3, 4MG5 and
4MH2) exhibited strong 3D8 VL-speciﬁc ﬂuorescence
signal, compared with untreated cells (Figure 4A).
Confocal ﬂuorescence microscopic analysis revealed that
all of 3D8 VL proteins dominantly accumulated in the
cytosol with little further traﬃcking into the nucleus
(Figure 4B and Supplementary Figure S5), like 3D8
scFv (7). To our best knowledge, this is the ﬁrst report
of single-domain antibodies with the ability to internalize
into living cells.
Soluble heparin substantially blocked the internaliza-
tion of 3D8 VLs (Figure 4C), indicating that 3D8 VLs
interact with negatively charged cell surface proteoglycans
prior to internalization, like 3D8 scFv (7). Thus, the cell-
penetrating ability of 3D8 VLs seems not to be cell type-
speciﬁc, like other cell-penetrating anti-DNA antibodies
and peptides (6,26). To elucidate the speciﬁc internal-
ization mechanism, HeLa cells were pre-treated with the
following pharmacological inhibitors prior to the addition
of 3D8 VLs to interfere with the three major endocytic
pathways: chlorpromazine (CPZ) to inhibit clathrin-
dependent endocytosis, methyl-b-cyclodextrin (MbCD)
to inhibit caveolae/lipid raft endocytosis, and cytochalasin
D (Cyt-D) to inhibit macropinocycosis [please refer to the
refs. (7,26) for details]. Flow cytometric analyses revealed
that pre-incubation of cells with MbCD (5mM), but
neither with CPZ (10mg/ml) nor Cyt-D (1mg/ml), led to
Table 2. Kinetic parameters of 3D8 VLs hydrolyzing activity with various 18-bp ss-DNAs and ss-RNAs, derived from the data given in
Figure 3
a
3D8
VLs
Kinetic parameters ss-DNA substrates (ss-RNA substrates)
b
A18 T18 C18 (G4T)3G3
c Her218(ss-RNA) N18(ss-RNA)
WT Km (nM) 644±18 568±14 522±18 543±12 549±13
(421±19)
587±11
(441±17)
kcat (s
 1)(  10
 3) 1.6±0.1 1.8±0.1 1.7±0.1 1.9±0.1 1.7±0.1
(1.8±0.1)
1.7±0.1
(1.7±0.1)
kcat/Km (nM
 1s
 1)(  10
 6) 2.5±0.4 3.2±0.2 3.3±0.1 3.4±0.2 3.0±0.2
(4.2±0.3)
2.8±0.1
(4.0±0.1)
4M Km (nM) 614±16 576±15 597±17 525±13* 584±15
(394±12)
576±10
(404±15)
kcat (s
 1)(  10
 3) 1.3±0.2 1.2±0.1* 1.9±0.1* 1.5±0.1 1.5±0.1
(1.8±0.1)
1.5±0.1
(1.6±0.1)
kcat/Km (nM
 1s
 1)(  10
 6) 2.1±0.1 2.1±0.1* 3.2±0.2* 2.9±0.1 2.5±0.2
(4.4±0.3)
2.6±0.2
(4.0±0.1)
4MG3 Km (nM) 684±21 829±14* 512±12 297±11* 507±14
(397±14)
559±10
(427±10)
kcat (s
 1)(  10
 3) 1.5±0.1 1.9±0.1 1.3±0.1 2.1±0.1* 1.7±0.1
(1.8±0.1)
1.6±0.1
(1.9±0.1)
kcat/Km (nM
 1s
 1)(  10
 6) 2.2±0.1 2.3±0.2* 2.6±0.1 7.1±0.3* 3.3±0.2
(4.6±0.2)
2.8±0.1
(4.5±0.2)
4MG5 Km (nM) 643±16 493±11 522±13 352±13* 643±12
(422±8.6)
601±14
(415±17)
kcat (s
 1)(  10
 3) 1.4±0.2 1.7±0.1 2.0±0.1 2.8±0.1* 1.7±0.1
(2.1±0.1)
1.5±0.1
(2.0±0.1)
kcat/Km (nM
 1s
 1)(  10
 6) 2.2±0.3 3.3±0.1 3.8±0.3 7.8±0.2* 2.7±0.1
(4.9±0.2)
2.5±0.2
(4.9±0.2)
4MH2 Km (nM) 758±14* 558±13 527±11 459±14 300±14*
(245±12*)
459±19
(395±7)
kcat (s
 1)(  10
 3) 1.2±0.1* 1.8±0.13 1.6±0.1 1.7±0.2 2.2±0.1*
(2.4±0.1*)
1.9±0.1
(2.0±0.1)
kcat/Km (nM
 1s
 1)(  10
 6) 1.6±0.1* 3.3±0.2 3.0±0.2 3.7±0.3 7.3±0.6*
(10.0±0.3*)
4.1±0.2
(5.1±0.4)
aEnzyme kinetic parameters were obtained by incubating each protein (100nM) with various substrate concentrations (16nM–2mM) at 37 C,
as described in Figure 3. All experiments were performed in triplicate and the results are represented as mean±SD. Signiﬁcant diﬀerence of
each kinetic parameter was determined using two-tailed Student’s t-test versus the control N18 substrate (*P<0.01).
bThe values for ss-RNA substrates, Her218 and N18, were presented in the parenthesis.
cDue to the diﬃculty in synthesizing the double labeled ss-DNA G18 FRET substrate, ss-DNA (G4T)3G3 was used as the G18 substrate.
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internalized (Figure 4C). These results strongly indicated
that 3D8 VLs are internalized via caveolae/lipid raft-
mediated endocytosis similar to 3D8 scFv (7).
Cell penetrating 3D8 VL variants selectively knockdown
target genes
The penetration of 3D8 VLs into living cells and their
dominant accumulation in the cytosol prompted us to
examine whether 3D8 VLs could selectively degrade
mRNAs carrying targeted sequences. When evaluated by
EGFP reporter gene with N-terminal G18 (G18-EGFP) in
HeLa cells, G18-selective 4MG3 and 4MG5 exhibited sig-
niﬁcant reductions in ﬂuorescence intensity for G18-EGFP
but not for intact EGFP (Figure 5A). Semi-quantitative
RT-PCRs (20) demonstrated that 4MG3 and 4MG5
selectively decreased only the amount of G18-EGFP
mRNA, without signiﬁcant eﬀects on mRNAs encoding
intact EGFP or a house-keeping gene, b-actin (Figure 5B).
This result was also reﬂected at the protein level
(Figure 5C). In contrast, 3D8 VL WT did not aﬀect the
expression levels of intact EGFP or G18-EGFP.
Her218-selective 4MH2 was incubated with HeLa cells
transfected with the full-length Her2 gene. For compari-
son, a siRNA targeting the same sequence of Her218 in the
Her2 gene (Her218-siRNA) was transfected into Her2-
transfected HeLa cells. Both 4MH2 and Her218-siRNA,
but not 3D8 VL WT, selectively down-regulated Her2
expression at the mRNA and protein levels, without
aﬀecting endogenous b-actin expression (Figure 5D and
E). Her2 gene silencing by 4MH2 at the mRNA and
protein levels was more eﬀective at the earlier time-point
of 24h post-treatment than Her218-siRNA, which exerted
substantial Her2 down-regulation after 48h post-
transfection.
Figure 4. 3D8 VL variants penetrate into living cells by interaction with heparin sulfate proteoglycan on the cell surface and localize dominantly
in the cytosol. (A) Cellular internalization of 3D8 VLs in HeLa (left panel) and SK-BR-3 (right panel) cells, monitored by ﬂow cytometry. HeLa
and SK-BR-3 cells were treated with each 3D8 VL (10mM) for 2h at 37 C and then with trypsin to remove surface bound proteins before
immunoﬂuorescent labeling of 3D8 VLs with rabbit anti-3D8 polyclonal antibodies and TRITC-labeled anti-rabbit IgG for ﬂow cytometry.
(B) Internalization and subcellular localization of 3D8 VLs in HeLa cells, untreated (‘control’) or treated with 10mM 3D8 VLs at 37 C for 2h
prior to analysis by confocal ﬂuorescence microscopy. 3D8 VLs were stained with rabbit anti-3D8 polyclonal antibodies and TRITC-labeled
anti-rabbit IgG (Red). Blue color depicts DAPI-stained nuclei. Centered single confocal sections are shown. Magniﬁcation,  400. (C) Eﬀect of
pre-treatment of soluble heparin or speciﬁc endocytosis inhibitors on the 3D8 VLs cellular uptake, analyzed by ﬂow cytometry. HeLa cells were
incubated with 3D8 VLs (10mM) for 2h at 37 C with or without pre-treatment of soluble heparin (100IU/ml), CPZ (10mg/ml), MbCD (5mM) and
Cyt-D (1mg/ml) for 30min prior to ﬂow cytometric analyses.
1604 Nucleic Acids Research, 2010,Vol.38, No. 5Like the 3D8 VL variants internalized as above, the
co-expression of 3D8 VL variants with target sequence-
carrying genes in HeLa cells selectively down-regulated
the expression levels of targeted proteins by reducing
their mRNA levels without signiﬁcantly aﬀecting oﬀ-
target genes (Supplementary Figure S6). This result
demonstrated that cytosolically expressed 3D8 VL
variants also selectively degrade their respective target
mRNAs to downregulate the expression of target
proteins without signiﬁcant eﬀects on oﬀ-targets.
Her218-selective 4MH2 eﬀectively knocks-down
endogenous Her2 expression to induce apoptotic cell
death in Her2-overexpressing cells
To determine whether Her218-selective 4MH2 could
knockdown the endogenous Her2 transcript by cellular
internalization, Her2-overexpressing breast carcinoma
SK-BR-3 cells (22) were treated with 4MH2, including
other 3D8 VLs for comparisons. 3D8 VL WT and G18-
selective 4MG3 and 4MG5 exhibited only slight decreases
in Her2 expression after 24h post-treatment (Figure 6A–
C), which was most likely due to non-speciﬁc oﬀ-target
eﬀects. In contrast, 4MH2 greatly reduced the cell
surface expression and mRNA levels of Her2 starting 2h
post-treatment, completely abolishing Her2 mRNA detec-
tion by 24h, with only a slight reduction in the mRNA
level of oﬀ-target b-actin at 48h (Figure 6A–C).
Compared with 4MH2, Her218-siRNA-mediated gene
silencing of Her2 was slower and less eﬃcient, decreasing
the cell surface expression and mRNA levels after 24h
post-transfection.
While elevated Her2 expression correlates with malig-
nant potential and poor prognosis of several types of car-
cinomas, silencing of Her2 by siRNA (22,23) or its
neutralization by intracellular antibody (intrabody) (27)
resulted in growth inhibition and cell death in Her2-
overexpressing tumor cells, including SK-BR-3 cells. To
investigate whether 4MH2-mediated Her2 gene silencing
can exert the similar activity, we treated Her2-
overexpressing SK-BR-3 and MDA-MB-231 cells with
Her218-selective 4MH2 and then monitored for the cell
death, including Her2-negative HeLa cells (27) as a
control. 4MH2 treatment signiﬁcantly induced cell death
which was proportional to the post-treatment period in
SK-BR-3 ( 75% after 48h) and MDA-MB-231 ( 65%
after 72h), but which was moderate in HeLa cells ( 30%
after 72h) (Figure 7A). Transfected Her218-siRNA also
induced cell death in Her2-overexpressing cells without
signiﬁcant cytotoxicity to HeLa cells. However, Her18-
siRNA-mediated cell death of Her2-overexpressing cells
was less eﬃcient than 4MH2 during the same period,
which is consistent with the relative knockdown eﬃciency
of Her2 (Figure 6).
To elucidate whether apoptosis is the principle mecha-
nism of 4MH2-mediated cell death, cells exposed to
4MH2 were labeled by dual staining of Annexin-V-FITC
and propidium iodide (PI) and then analyzed by ﬂow
cytometry (19). SK-BR-3 and MDA-MB-231 cells
treated with 4MH2 were signiﬁcantly labeled as early
apoptotic cells by Annexin-V-FITC positive staining
(Figure 7B), similar to Her218-siRNA, suggesting that
4MH2 induced apoptotic cell death in the Her2-
overexpressing cells. 3D8 VL WT and G18-selective
4MG3 and 4MG5 caused  30–40% cell death after 72h
post-treatment, regardless of the Her2 cellular expression
level, demonstrating that 3D8 VLs caused some
cytotoxicity, which was probably due to non-speciﬁc
cellular RNA hydrolysis (7). However, diﬀerences in the
Figure 5. Target gene silencing activity of cell-penetrating 3D8 VL variants in HeLa cells expressing exogenous targeted genes. (A–C) HeLa cells
were untransfected (‘control’) or transfected with plasmids encoding EGFP or G18-EGFP, and 12h later either untreated or treated at 37 C for 2h
with 3D8 VL WT (10mM) and G18-selective 4MG3 (10mM) and 4MG5 (10mM), and further incubated for 12h before EGFP expression analyses by
ﬂow cytometry (A), RT–PCR (B) and western blotting (C). (D and E) Her2-negative HeLa cells were untransfected (‘control’) or transfected with a
plasmid encoding the full-length Her2 gene, and 24h later were either untreated or treated at 37 C for 2h with 3D8 VL WT (10mM) and Her218-
selective 4MH2 (10mM). After further incubation for 24 or 48h, Her2 expression was analyzed by RT-PCR (D) and western blotting (E). After 24h
post-transfection with Her2 gene, HeLa cells were also transfected with Her218-siRNA (500nM) prior to analyses of Her2 expression at the indicated
time. (B–E) Endogenous b-actin served as the protein loading and mRNA abundance control for western blotting and RT-PCR analyses,
respectively.
Nucleic Acids Research,2010, Vol.38, No. 5 1605cell death exerted by 4MH2 ( 75%) and other 3D8 VLs
( 30–40%) in Her2-overexpressing cells could be
attributed the apoptotic cell death induced by the Her2
gene-silencing eﬀects of 4MH2.
DISCUSSION
Antibodies that normally lack the ability to penetrate into
living cells have been therapeutically used as targeting
proteins, including mainly soluble or cell-surface
Figure 7. Cell-penetrating Her218-selective 4MH2 induces apoptotic cell death of Her2-overexpressing cells. (A) Cell viability assay of
Her2-overexpressing SK-BR-3 and MDA-MB-231 cells and Her2-negative HeLa cells at the indicated periods of post-treatment with 3D8 VLs
(10mM) for 2h at 37 C or post-transfection of Her218-siRNA (500nM), as monitored by the MTT assay. Percent cell viability was calculated with
respect to the untreated control cells. (B) Flow cytometry analysis of Annexin-V-FITC and PI staining of Her2-overexpressing SK-BR-3 and
MDA-MB-231 cells at 12h post-treatment with medium only (‘control’) or with 3D8 VLs (10mM) for 2h at 37 C, or at 12h post-transfection
with Her218-siRNA (500nM). In the dot plots, Annexin-V-FITC
+/PI
  cells (lower right quadrant, % shown) and Annexin-V-FITC
+/PI
+ cells
(upper right quadrant, % shown) are considered as ‘early apoptotic’ and ‘dead’ cells, respectively.
Figure 6. Cell-penetrating Her218-selective 4MH2 knocks-down endogenous Her2 expression in Her2-overexpressing SK-BR-3 cells. SK-BR-3 cells
were untreated (‘control’) or treated with 3D8 VLs (10mM) for 2h at 37 C, or transfected with Her218-siRNA (500nM). Her2 expression was
monitored at the cell-surface by ﬂow cytometry (A), at the mRNA level by RT-PCR (B) and at the protein level by western blotting (C) at indicated
periods of post-treatment with 3D8 VLs or post-transfection with Her218-siRNA (500nM). Endogenous b-actin served as the protein loading and
mRNA abundance control for western blotting and RT-PCR analyses, respectively. ‘Control’ indicates untreated cells.
1606 Nucleic Acids Research, 2010,Vol.38, No. 5expressed antigens (15,19,28). The targeting of
intracellular proteins has been achieved by intrabodies
(11,28,29). However, intrabodies have never been
exploited to knockdown speciﬁc proteins at the post-
transcriptional mRNA level. Here, we have developed
target sequence-selective, hydrolyzing, single-domain
antibodies of 3D8 VL variants that can penetrate into
living cells and accumulate mostly in the cytosol. These
cell-penetrating antibodies (transbodies) recognize and
degrade targeted mRNAs, but not proteins, resulting in
targeted gene silencing.
We engineered in vitro the sequence non-speciﬁc
DNA/RNA-hydrolyzing 3D8 VL, which has the typical
immunoglobulin fold of b-sandwich, into target
sequence-selective hydrolyzing variants by randomizing
one-sided b-sheet residues. In vitro engineering of anti-
DNA/RNA antibodies that speciﬁcally recognize and
hydrolyze speciﬁc DNA/RNA antigens has never been
reported, although an RNA-binding Fab has been engi-
neered to speciﬁcally recognize the targeted RNA tertiary
structure (30) and sequence-speciﬁc DNA binding
antibodies have been raised in vivo from mice (31,32).
Our results suggest that proteins with b-sheet structure
can be used as a scaﬀold to engineer sequence-speciﬁc
ss-DNA/RNA binding proteins, as a-helical zinc-ﬁnger
protein does in speciﬁc-speciﬁc ds-DNA-binding proteins
(33). However, random mutations introduced into the
highly conserved framework regions of 3D8 VL, which
are otherwise buried in VH–VL interface in IgG format,
might induce immunogenic response in vivo.
Even though the 18-bp ss-DNAs were employed as
screening substrates rather than ss-RNAs due to the
higher nucleolytic stability, the selected 3D8 VL variants
showed very similar sequence-selective binding and
hydrolyzing activities for the targeted sequences in ss-
RNA form to those in ss-DNA form in vitro (Table 1
and 2), resulting in the preferential hydrolysis of
mRNAs carrying the target sequences in the cytosol of
cells. In DNA/RNA–protein interactions, stacking and
electrostatic interactions play a key role in providing
aﬃnity, whereas hydrogen bonds between nucleobase
and amino acids dominantly contribute to the sequence-
speciﬁcity as well as aﬃnity (34). The rank orders of
nucleobase–amino acid type correlations have shown
strong similarities between the DNA and RNA cases
(34,35), suggesting the minor diﬀerences between ss-
DNA and ss-RNA, including thymine (5-methyluracil)
and deoxyribose in DNA in place of uracil and ribose in
RNA, do not signiﬁcantly aﬀect the sequence speciﬁcity.
Thus, the similar preferential recognition of 3D8 VL
variants to their target sequences in either ss-DNA or ss-
RNA form suggests that hydrogen bonds between
nucleobase and amino acids mainly contribute to their
sequence-speciﬁcity.
No common patterns of amino acid substitutions were
observed among 3D8 VL variants isolated against the
same substrates, G18 and Her218 (Supplementary Figure
S3), suggesting that substituted residues at each position
may be involved in more subtle, context-dependent inter-
actions with the target sequences, like the zinc ﬁnger-DNA
recognition (33). While random mutations without bias to
particular amino acids at the targeted residues were
observed in the initial library, most of substitutions in
the selected 3D8 VL variants occurred with hydrophilic
residues (Arg, Asn, Gln, Glu, Ser, Lys, Asp and His),
which could readily contribute to base-speciﬁc recognition
by hydrogen bonds (34). Particularly, the selected 3D8 VL
variants showed strong preference for Arg substitution at
many residues facing outward, particularly for G18-selec-
tive 3D8 VL variants (Supplementary Figure S3). Arg is
the most common amino acid interacting with guanine
base, the pair of which can form up to four hydrogen
bonds, in the analysis of amino acid-base contacts in
protein–RNA complexes (34,35). Detailed analysis of the
contribution of each substitution to the preferential inter-
action with target sequences should be waited until
the complex structures of 3D8 VL variants with target
substrates are obtained.
Many anti-DNA/RNA hydrolyzing antibodies, pre-
ferentially found in humans and mice with autoimmune
diseases, have been reported to have the ability to pene-
trate into living cells (6,36–39). Though detailed structural
and mechanistic bases how they can cross the plasma
membrane of cells remain to be resolved, many studies
have suggested that their common feature of possessing
a large number of positively-charged amino acids, such as
Arg and Lys, in the complementarity-determining regions
(CDRs) of VH and/or VL domains due to their antigen
binding properties, can be attributed to their internalizing
capacity (6,36–39). Thus, like cell-penetrating peptides,
non-speciﬁc electrostatic interactions of anti-DNA/
RNA antibodies with negatively charged cell surface
matrix, such as heparan sulfate proteoglycans, have been
proposed to contribute to their cell-penetrating activity
without cell-type speciﬁcity (40,41). 3D8 VL WT and its
variants eﬃciently internalized into the cytosol of living
cells most likely by the caveolae/lipid raft-mediated
endocytic pathway (Figure 4), like 3D8 scFv (7). Three-
dimensional structural analysis of 3D8 VL (17) reveals a
continuous patch clustered with positively-charged amino
acids composed of Arg27f, Arg29 and Lys30 in CDR1,
which is also conserved in the selected 3D8 VL variants
(Supplementary Figure S3). This unusual cationic
property of 3D8 VLs might explain their cellular internal-
ization capacity, like other cell-penetrating anti-DNA/
RNA antibodies (37–41).
Cytoplasmic accumulation of cellular internalized 3D8
VL variants makes it possible to induce gene silencing of
targeted genes, like RNAi-mediated gene silencing that
primarily occurs in the cytosol (1–3). The knockdown
eﬃciencies of the 3D8 VL variants ranged from
10–100% and increased with the post-treatment period.
These ranges are similar to those achieved by conventional
siRNA techniques (1–3). Her218-selective 4MH2 induced
apoptotic cell death for Her2-overexpressing tumor cells
by down-regulating Her2 expression (Figure 6 and 7),
indicating that it may have potential as an anti-cancer
agent. Compared with Her218-siRNA, the extent to
which 4MH2 could knock-down Her2 over a short
period ( 2h) of post-treatment (Figure 6), both at the
mRNA and protein level, was remarkable. 3D8 VLs in
HeLa and SK-BR-3 cells were diﬀused throughout the
Nucleic Acids Research,2010, Vol.38, No. 5 1607cytosol within  2h of medium treatment, with little accu-
mulation in the nucleus, similar to 3D8 scFv (7). The eﬃ-
cient gene silencing eﬀects achieved immediately after
cellular internalization of 3D8 VLs distinguishes 3D8
VLs from siRNAs which require at least 12–18h for eﬀec-
tive gene silencing (1–3).
3D8 VL variants exerted signiﬁcant cytotoxicity ( 30–
40% after 72h) compared with siRNA (<10% after 72h).
The selected 3D8 VL variants showed moderate binding
aﬃnities of KD  10
 7–10
 8M with the target substrates
and only  2–5-fold greater selective hydrolyzing activities
for the target sequences than oﬀ-targets (Table 1 and 2),
which is rather low target speciﬁcity compared with other
RNA–protein speciﬁc interactions (30,34,35). Structural
features and molecular docking analysis revealed that
3D8 VLs may interact with only  5–7 bases of ss-RNA.
This suggests that the limited target sequence recognition
caused non-speciﬁc degradation of other cytosolic RNAs
(7), resulting in more cytotoxicity than the 19-bp-targeting
siRNA. To minimize oﬀ-target eﬀects, modular units of
3D8 VL variants could be linked to confer higher
speciﬁcity and aﬃnity for long RNA sequences of up
to 12–18bp, as has previously been done for zinc-ﬁnger
proteins (33).
Interfering transbody-mediated gene silencing may
oﬀer several advantages over conventional nucleic-acid
based approaches (1–4,10,11), including cell-penetrating
ability without the need for exogenous carriers, RNA deg-
radation without external RNases, no nuclease suscepti-
bility, and immediate gene-silencing eﬀects after cellular
internalization. These distinct features make interfering
transbody an attractive alternative to nucleic-based
approaches for modulating gene expression in functional
genomics or in therapeutic approaches to diseases
such as cancer and viral infections. However, many
issues must be addressed to make interfering transbody
a more practical and powerful gene-silencing tool for in
vivo applications, including decreasing the oﬀ-target
eﬀects and conferring cell- or tissue-speciﬁc penetrating
abilities.
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